Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTLOU6)

• Drug Name: CLEBOPRIDE Drug Info
• Synonyms: Clebopride; 55905-53-8; Cleboril; Clebopridum [INN-Latin]; Cleboprida [INN-Spanish]; 4-amino-N-(1-benzylpiperidin-4-yl)-5-chloro-2-methoxybenzamide; UNII-I0A84520Y9; LAS 9273; EINECS 259-885-9; C20H24ClN3O2; BRN 0493934; CHEMBL325109; I0A84520Y9; 4-Amino-N-(1-benzyl-4-piperidyl)-5-chloro-o-anisamide; clebopride malate; 4-Amino-5-chloro-2-methoxy-N-(1-benzyl-4-piperidyl)benzamide; Clebopridum; Cleboprida; N-(1'-Benzyl-4'-piperidyl)-2-methoxy-4-amino-5-chlorobenzamide; BENZAMIDE, 4-AMINO-5-CHLORO-2-METHOXY-N-(1-(PHENYLMETHYL)-4

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 2780
  ChEBI ID: CHEBI:92309
  CAS Number: CAS 55905-53-8
  TTD Drug ID: DMTLOU6

Molecule-Related Drug Atlas

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[4]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[5]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[6]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[7]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[8]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[9]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[10]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[11]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[12]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[13]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[14]
Haloperidol	DM96SE0	Delirium		Approved	[15]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[16]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[17]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[18]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[19]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[20]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[21]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[22]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[23]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[24]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[25]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[26]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[27]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[27]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[28]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[29]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[30]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[31]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[27]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[2]
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[3]

References

• [1] Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
• [2] Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J Med Chem. 2004 Sep 23;47(20):4818-28.
• [3] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [4] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [6] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [7] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [8] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [9] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [11] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [12] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [13] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [14] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [15] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [16] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [17] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [18] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [20] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [21] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [22] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [23] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [24] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [25] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [26] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [27] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [28] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [29] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [30] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [31] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.